Patel Featured on BPCIA Litigation Settlements

Hatch-Waxman and Biosimilars Practice Group Leader Sailesh Patel explained why some biosimilar companies engaged in Biologics Price Competition and Innovation Act (BPCIA) litigation may choose to settle.

Sal said, “I think just as we see in Hatch-Waxman cases, I think there will be creative settlements that will be employed to end the uncertainty and the cost of the [BPCIA] litigation, which I anticipate is going to be much higher than what we see with Hatch-Waxman litigation.”

Watch the full video here.